×
Replimune Total Liabilities 2018-2025 | REPL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Replimune total liabilities from 2018 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Replimune Total Liabilities 2018-2025 | REPL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Replimune total liabilities from 2018 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.7B
Amgen (AMGN)
$161.5B
Gilead Sciences (GILD)
$142.5B
Vertex Pharmaceuticals (VRTX)
$123.1B
Bristol Myers Squibb (BMY)
$98.7B
GSK (GSK)
$81B
CSL (CSLLY)
$78.2B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$42.1B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$27.4B
Royalty Pharma (RPRX)
$20.3B
Biogen (BIIB)
$19.8B
Insmed (INSM)
$18.3B
Illumina (ILMN)
$15.8B
Genmab (GNMSF)
$14B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.3B
Exelixis (EXEL)
$12.3B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$10.8B
Ascendis Pharma (ASND)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Regencell Bioscience Holdings (RGC)
$8.2B
Roivant Sciences (ROIV)
$7.9B